Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04955015
Other study ID # M2019292
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date July 31, 2023

Study information

Verified date June 2021
Source Peking University Third Hospital
Contact Ran Huo, Dr.
Phone 010-82264374
Email ransmile216@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Stroke is one of the leading causes of death and disability-adjusted life-years worldwide. Carotid high-risk atherosclerotic plaques are considered to be one of the major sources of ischemic stroke. The present study aimed to investigate the relationship of carotid plaque characteristics with brain perfusion and cognitive function in patients undergoing carotid endarterectomy.


Description:

Cerebrovascular disease is the first cause of death and adult disability in China. More than 75% of the patients in China have ischemic cerebrovascular disease, and about 33.3% of them have ipsilateral extracranial carotid stenosis. One of the main causes of carotid stenosis is atherosclerosis. Atherosclerotic plaques can be divided into two types: stable plaques and vulnerable plaques. Vulnerable plaque has the tendency to rupture, prone to thrombosis and rapid progression of dangerous plaque. Its pathological characteristics are mainly as follows: thin fibrous cap (or fibrous cap has been broken), large lipid nucleus, massive hemorrhage in plaque, rich in inflammatory cells, abundant neovascularization and plaque surface calcification. Vulnerable plaque is the main cause of stroke. At present, high-resolution magnetic resonance imaging combined with multi sequence is one of the best methods to evaluate carotid artery stenosis, which is helpful to analyze plaque characteristics. At present, the main treatment methods of carotid artery stenosis are: carotid endarterectomy (CEA) and carotid angioplasty with stenting (CAS). Large scale multicenter prospective randomized trials and meta-analysis have established CEA as the gold standard for the treatment of carotid arerosclerotic stenosis. Studies have shown that the ipsilateral cerebral perfusion is continuously decreased due to carotid artery stenosis, and CEA operation can relieve the vascular stenosis and improve the cerebral perfusion. However, the relationship between cerebral perfusion improvement after CEA and the quantitative characteristics of vulnerable plaque is still lack of sufficient evidence. Vascular cognitive impairment is closely related to the progress of carotid stenosis. The main mechanisms are microemboli formation, white matter injury and central nervous function decline caused by long-term chronic hypoperfusion. The formation and continuous hypoperfusion of microemboli further increase the burden of white matter disease. Studies have shown that the visual spatial executive ability, naming ability, attention ability and abstract profile ability of patients after CEA are significantly improved. However, there is still insufficient evidence about the relationship between the MRI features of vulnerable carotid plaques and the improvement of cognitive function after CEA. We hope to achieve the following goals: 1) to explore the associations between carotid vulnerable plaque characteristics and cerebral perfusion in patients undergoing CEA; 2) to explore the associations between the characteristics of vulnerable carotid plaques and cognitive function in patients undergoing CEA.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 31, 2023
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender All
Age group 30 Years and older
Eligibility Inclusion Criteria: 1. Over 30 years old; 2. The patients with symptomatic (>50%) or asymptomatic carotid stenosis (> 70%) measured by computed tomography angiography (CTA) or B-mode ultrasonography 3. CEA operation will be performed in our hospital. Exclusion Criteria: 1. The history of CEA operation in the last 3 months; 2. Diseases (AF, valve diseases, etc.) that may cause cardiac thrombosis; 3. Contraindications of MR examination (vascular stent implantation, pacemaker, metal or magnetic plants in vivo, claustrophobia, etc.) were found; 4. Contraindications of contrast agents: such as renal failure, iodine or gadolinium contrast agent allergy; 5. Having heart or respiratory failure; 6. Serious consciousness disorder (coma, etc.); 7. Brain tumor; 8. Acute cerebral hemorrhage; 9. Pregnant women or planned pregnancies in the past 2 years; 10. Who does not agree to sign the informed consent.

Study Design


Intervention

Procedure:
carotid endarterectomy
patients with carotid atherosclerosis refering to CEA

Locations

Country Name City State
China Peking University Third Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary brain perfusion perioperative brain perfusion and changes of brain perfusion in patients underging CEA From preoperative to 24 months after operation (CEA)
Primary cognitive function perioperative cognitive function and cognitive changes in patients underging CEA From preoperative to 24 months after operation (CEA)
See also
  Status Clinical Trial Phase
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Recruiting NCT05680935 - microRNAs in the Diagnosis of Atherosclerotic Plaque Instability N/A
Recruiting NCT06091319 - Florbetaben for Imaging of Vascular Amyloid
Recruiting NCT06211127 - Safety and Efficacy of Cold Laser Plaque Ablation for Lower Limb Arterial Stenosis and Occlusive Lesions N/A
Withdrawn NCT05908513 - NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM Phase 1
Suspended NCT03928769 - PROGENitors, TELomeres and ARTerial Aging
Not yet recruiting NCT04277702 - Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease Phase 3
Not yet recruiting NCT04303546 - VOPITB a New Devices to Determine Peripheral Arterial Stiffness: Validation Study
Completed NCT05214872 - The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
Completed NCT02715830 - Randomized Clinical Trial in Bellow-the-knee Angioplasty. Treatment of One or More Than One Artery. Phase 4
Not yet recruiting NCT06447701 - Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis Phase 3
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Completed NCT04198896 - The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)
Completed NCT03499496 - Screening for Atherotic Plaques by Ultrasound for Assessing Cardiovascular Risk
Completed NCT05118542 - Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis Phase 3
Recruiting NCT04365062 - Clinical Study of Excimer Laser and Drug Coated Balloon Versus Excimer Laser and Plain Balloon Versus Plain Balloon and Drug Coated Balloon to Treat Femoropopliteal In-stent Restenosis N/A
Completed NCT03962686 - Molecular Mechanisms and Carotid Atherosclerosis
Active, not recruiting NCT04666584 - Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis N/A
Recruiting NCT05797376 - Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation Phase 4
Not yet recruiting NCT04303351 - Periodontitis and Atherosclerotic-related Arterial Stenosis